InvestorsHub Logo
Followers 74
Posts 15845
Boards Moderated 0
Alias Born 04/26/2010

Re: sharonc post# 127394

Saturday, 05/05/2018 11:53:58 AM

Saturday, May 05, 2018 11:53:58 AM

Post# of 426871
Just read CELG's C transcript, and they blatantly avoided answering a question about whether they needed to do a a two-year carcinogenicity study in animals for ozanimod - they claimed resubmission of NDA expected in Q1/19, but didn't explain how they're going to achieve it. They have a big problem on their hands in my view - the metabolite that's the problem is only created in humans, not animals - so to fully test it to meet FDA's concerns they'll have to synthesize the metabolite, if that's even possible - might be more difficult than they think.

These kinds of problems with man-made chemical drugs is one reason why V is such a wonderful drug - made by nature, safe as hell, no hidden problems lurking underneath the surface - and I'll bet someday high dose EPA will be shown to have cancer protective properties as well (instead of possibly causing cancer like ozanimod).

The Thought Police: To censor and protect. Craig Bruce

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News